These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17909310)

  • 41. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deprenyl--past and future. Proceedings of a symposium. Lake Starnberg, Bavaria, 1995.
    J Neural Transm Suppl; 1996; 48():1-112. PubMed ID: 9102455
    [No Abstract]   [Full Text] [Related]  

  • 43. Monoamine oxidase inhibitor efficacy in depression and the "cheese effect".
    Sandler M
    Psychol Med; 1981 Aug; 11(3):455-8. PubMed ID: 6791195
    [No Abstract]   [Full Text] [Related]  

  • 44. Low dose selegiline (L-Deprenyl) in social phobia.
    Simpson HB; Schneier FR; Marshall RD; Campeas RB; Vermes D; Silvestre J; Davies S; Liebowitz MR
    Depress Anxiety; 1998; 7(3):126-9. PubMed ID: 9656093
    [No Abstract]   [Full Text] [Related]  

  • 45. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 46. Big first scored with nerve diseases.
    Lewin R
    Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract]   [Full Text] [Related]  

  • 47. MAO inhibitors: risks, benefits, and lore.
    Wimbiscus M; Kostenko O; Malone D
    Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New drug treatment for Parkinson's disease.
    FDA Consum; 2006; 40(4):7. PubMed ID: 17245831
    [No Abstract]   [Full Text] [Related]  

  • 49. Using monoamine oxidase type B inhibitors in Parkinson's disease.
    Ben-Shlomo Y; Bhatia K
    BMJ; 2004 Sep; 329(7466):581-2. PubMed ID: 15361418
    [No Abstract]   [Full Text] [Related]  

  • 50. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.
    Richard IH; Kurlan R; Tanner C; Factor S; Hubble J; Suchowersky O; Waters C
    Neurology; 1997 Apr; 48(4):1070-7. PubMed ID: 9109902
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
    Berry MD; Juorio AV; Paterson IA
    Prog Neurobiol; 1994 Oct; 44(2):141-61. PubMed ID: 7831475
    [No Abstract]   [Full Text] [Related]  

  • 52. 'On-off' phenomenon: description, incidence and management.
    Dubuis R
    Eur Neurol; 1987; 27 Suppl 1():3-8. PubMed ID: 3123241
    [No Abstract]   [Full Text] [Related]  

  • 53. [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa].
    Gerstenbrand F; Prosenz P
    Praxis; 1965 Nov; 54(46):1373-7. PubMed ID: 5899418
    [No Abstract]   [Full Text] [Related]  

  • 54. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation.
    Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
    Int J Geriatr Psychiatry; 2002 Apr; 17(4):391-2. PubMed ID: 11994896
    [No Abstract]   [Full Text] [Related]  

  • 56. Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits.
    Uzun M; Alp R; Uzlu E; Alp S; Citil M; Topcu B; Erdogan HM
    Eur Rev Med Pharmacol Sci; 2009; 13(2):95-8. PubMed ID: 19499843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse effects of dopamine potentiation by long-term treatment with selegiline.
    Hollán S; Vécsei L; Magyar K
    Mov Disord; 2004 Jan; 19(1):107-9. PubMed ID: 14743370
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME
    J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of Alzheimer's disease -- searching for a breakthrough, settling for less.
    Drachman DA; Leber P
    N Engl J Med; 1997 Apr; 336(17):1245-7. PubMed ID: 9110915
    [No Abstract]   [Full Text] [Related]  

  • 60. Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.
    Prescrire Int; 2003 Oct; 12(67):179. PubMed ID: 14619897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.